Boosting the pharmaceutical industry’s AI capabilities could help more than 400 million patients globally, according to a new report released by the Institution of Engineering and Technology (IET).
During the past 12 months, AI has played a fundamental role in helping nations across the world tackle COVID-19. It enabled scientists to rapidly identify drugs that could be repurposed to treat the virus, including dexamethasone; the anti-inflammatory that played a vital role during the peak of the pandemic by significantly reducing risk of death in hospitalised patients[1].
The IET is calling on government to take urgent action and invest in machine learning to help tackle other national and global health challenges and futureproof our healthcare system. From rare forms of lung disease such as Alpha-1 Antitrypsin Deficiency, to uncommon fungal infections like Zygomycosis, AI streamlines early research and facilitates treatment breakthroughs which could help millions of patients globally.
Read more here